Table 2.
Plasma lipid/lipoprotein profile of Alzheimer’s disease patients and control subjects
| AD (n = 70) |
CN (n = 74) |
P | |
|---|---|---|---|
| Total cholesterol (mg/dL) | 193.7 ± 44.3 | 198.4 ± 39.7 | 0.64 |
| Unesterified cholesterol (mg/dL) | 44.0 ± 15.7 | 56.0 ± 9.8 | < 0.0001 |
| Unesterified/total cholesterol | 0.23 ± 0.08 | 0.28 ± 0.03 | 0.0002 |
| Cholesteryl esters (mg/dL) | 251.3 ± 70.1 | 244.9 ± 54.4 | 0.66 |
| LDL cholesterol (mg/dL) | 117.9 ± 38.6 | 106.9 ± 32.1 | 0.06 |
| HDL cholesterol (mg/dL) | 54.0 ± 16.1 | 57.1 ± 12.1 | 0.11 |
| Non-HDL cholesterol (mg/dL) | 139.7 ± 40.9 | 137.9 ± 36.3 | 0.78 |
| Triglycerides (mg/dL) | 105.0 (82; 129) | 106.5 (75; 123) | 0.95 |
| Phospholipids (mg/dL) | 209.2 ± 39.8 | 212.3 ± 42.1 | 0.94 |
| Apolipoprotein A-I (mg/dL) | 143.2 ± 27.8 | 138.8 ± 20.9 | 0.29 |
| Apolipoprotein A-II (mg/dL) | 28.6 ± 4.7 | 29.1 ± 7.3 | 0.83 |
| Apolipoprotein E (mg/dL) | 3.4 ± 1.1 | 2.9 ± 0.8 | 0.37 |
| Apolipoprotein B (mg/dL) | 96.7 ± 24 | 110.9 ± 31.4 | 0.03 |
| LCAT activity (nmol/mL/h) | 29.4 ± 12.4 | 36.4 ± 7.8 | < 0.0001 |
| CER (nmol/mL/h) | 30.2 ± 12.9 | 35.9 ± 12.0 | 0.02 |
| Preβ-HDL (% of total apoA-I) | 9.95 ± 6.40 | 13.63 ± 4.12 | 0.03 |
| Aqueous diffusion CEC (%) | 6.7 ± 1.1 | 5.3 ± 1.0 | < 0.0001 |
| ABCG1 CEC (%) | 4.8 ± 0.8 | 5.7 ± 1.5 | 0.0004 |
| ABCA1 CEC (%) | 3.7 ± 0.8 | 4.4 ± 1 | 0.001 |
AD Alzheimer’s disease, CN cognitive normal controls, LCAT lecithin:cholesterol acyltransferase, CER cholesterol esterification rate, CEC, cholesterol efflux capacity, ABCG1 ATP-binding cassette G1, ABCA1 ATP-binding cassette A1
Data are reported as mean ± SD or median (1st; 3rd quartile). AD and controls were compared by the Wilcoxon rank-sum test